Clinical Trial

Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse

Study acronym: FLECAPRO
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
FLECAPRO is a randomized controlled crossover trial assessing the effect and safety of adding flecainide to standard beta-blocker therapy to reduce the burden of ventricular arrhythmias in patients with arrhythmic mitral valve prolapse. The primary endpoint of will be assessed using an implantable loop recorder with blinded endpoint adjudication.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-11-16; most recent amendment 2025-07-29.
Status change: Not Yet Recruiting → Recruiting 2023-01-06
Trial Details
NCT Number NCT05631730
Lead Sponsor Oslo University Hospital
Collaborators: The Research Council of Norway, University of Oslo
Conditions Mitral Valve Prolapse, Ventricular Arrhythmias and Cardiac Arrest
Enrollment 50 participants
Start Date 2023-01-04
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-30